Verona Pharma plc Stock price

Equities

VRNA

US9250501064

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
16.09 USD -2.48% Intraday chart for Verona Pharma plc +0.88% -19.06%
Sales 2024 * 24.87M 31.4M Sales 2025 * 118M 149M Capitalization 1.06B 1.34B
Net income 2024 * -75M -94.67M Net income 2025 * -24M -30.3M EV / Sales 2024 * 35.2 x
Net cash position 2024 * 184M 232M Net cash position 2025 * 146M 185M EV / Sales 2025 * 7.73 x
P/E ratio 2024 *
-28 x
P/E ratio 2025 *
-100 x
Employees 79
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.48%
1 week+1.00%
Current month-6.56%
1 month-10.16%
3 months-21.40%
6 months-5.02%
Current year-19.06%
More quotes
1 week
15.63
Extreme 15.63
16.77
1 month
15.11
Extreme 15.11
18.49
Current year
15.11
Extreme 15.11
20.67
1 year
11.83
Extreme 11.83
23.81
3 years
3.41
Extreme 3.4078
26.44
5 years
0.00
Extreme 0
26.44
10 years
0.00
Extreme 0
26.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 20-01-31
Director of Finance/CFO 61 20-02-29
Chief Tech/Sci/R&D Officer - 22-12-31
Members of the board TitleAgeSince
Director/Board Member 79 16-06-16
Director/Board Member 60 16-09-11
Chairman 69 14-11-30
More insiders
Date Price Change Volume
24-03-28 16.09 -2.48% 309,348
24-03-27 16.5 +2.23% 359,388
24-03-26 16.14 +2.74% 397,379
24-03-25 15.71 -2.24% 294,308
24-03-22 16.07 +0.75% 364,289

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
16.09 USD
Average target price
33.14 USD
Spread / Average Target
+105.98%
Consensus
  1. Stock
  2. Equities
  3. Stock Verona Pharma plc - Nasdaq